Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1Phase 1 1

Status

Completed 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 2

Conditions

Multiple Myeloma 3Neoplasms, Plasma Cell 2

Interventions

Dexamethasone 111Cyclophosphamide 99Melphalan 91Bortezomib 69Peripheral Blood Stem Cell Transplantation 64Lenalidomide 58fludarabine phosphate 56Busulfan 54Filgrastim 50Tacrolimus 38Antilymphocyte Serum 38Thalidomide 36Radiotherapy 36Mycophenolic Acid 33fludarabine 28Cyclosporine 26Methotrexate 25Etoposide 22Calcium Dobesilate 22Whole-Body Irradiation 21Prednisone 21Methylprednisolone 20sargramostim 19pomalidomide 19Granulocyte Colony-Stimulating Factor 18carfilzomib 16daratumumab 15Cord Blood Stem Cell Transplantation 15Carmustine 14Rituximab 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Neoplasms, Plasma Cell × Hydroxychloroquine × Plasma cell × Clear all
NCT00568880 2020-02-07

Hydroxychloroquine and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma

Abramson Cancer Center at Penn Medicine

Phase 1 Completed
25 enrolled
Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

NCT01396200 2013-02-26

Cyclophosphamide and Pulse Dexamethasone With Rapamycin or Hydroxychloroquine

Abramson Cancer Center at Penn Medicine

Phase EARLY_PHASE1 Completed
6 enrolled
Plasma cell

Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡